Topical treatment of seasonal allergic rhinitis with a beta-adrenoceptor stimulant (KWD 2131).
During 4 weeks of the grass pollen season in the south of Sweden 27 patients with seasonal allergic rhinitis were treated topically with a beta-adrenoceptor stimulant, KWD 2131, which in an earlier rhinomanometric study had shown a prophylactic effect at nasal allergen provocations in hay-fever patients. A clinical effect of KWD 2131 could not be documented in this randomized placebo-controlled, double-blind comparative study. The results contribute to conclusions in the clinical implications of rhinomanometric data.
D000281:Administration, Intranasal; D000293:Adolescent; D000318:Adrenergic beta-Agonists; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy*; D013726:Terbutaline / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000318:Adrenergic beta-Agonists; C025075:KWD 2131; D013726:Terbutaline